Zymeworks Inc. (ZYME)
| Market Cap | 525.14M |
| Revenue (ttm) | 412.48M |
| Net Income (ttm) | 124.34M |
| Shares Out | 64.04M |
| EPS (ttm) | 1.90 |
| PE Ratio | 4.32 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 333,104 |
| Open | 8.12 |
| Previous Close | 8.19 |
| Day's Range | 8.07 - 8.31 |
| 52-Week Range | 4.11 - 10.80 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 14.00 (+70.73%) |
| Earnings Date | May 3, 2023 |
About ZYME
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or me... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for ZYME stock is "Buy." The 12-month stock price forecast is $14.0, which is an increase of 70.73% from the latest price.
News
Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced the acceptance of...
Zymeworks Offers Hope for More than Just Long-Term Investors
Zymeworks Inc. (NASDAQ: ZYME) stock is up almost 5% after beating analysts' expectations for revenue and earnings in its March 7, 2023 earnings report. The clinical-stage biopharmaceutical company is ...
Zymeworks Inc. (ZYME) Q4 Earnings and Revenues Beat Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 0.65% and 8.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results f...
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management w...
Zymeworks Inc. (ZYME) Flat As Market Sinks: What You Should Know
Zymeworks Inc. (ZYME) closed the most recent trading day at $8.57, making no change from the previous trading session.
Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management w...
Zymeworks Inc. (ZYME) to Report Q4 Results: Wall Street Expects Earnings Growth
Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Zymeworks (ZYME) Beat Expectations This Earnings Season?
In the absence of a marketed product, Zymeworks (ZYME) is expected to provide an update on its pipeline candidates, mainly zanidatamab for the treatment of patients with HER2-expressing cancers, at th...
Zymeworks shares gain on promising data for cancer drug in development with Jazz Pharmaceuticals
Shares of Zymeworks Inc. ZYME, rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. JAZZ, -0.58% said their experimental cancer drug had an overall survival rat...
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease control rate (DCR) of 92%, and median prog...
How Much Upside is Left in Zymeworks Inc. (ZYME)? Wall Street Analysts Think 65.75%
The mean of analysts' price targets for Zymeworks Inc. (ZYME) points to a 65.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a...
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced updated key str...
Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why
Zymeworks (ZYME) recently entered a collaboration with Jazz Pharmaceuticals (JAZZ) for its lead pipeline candidate. This has been a significant catalyst for the stock.
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
Zymeworks Inc. (ZYME) Upgraded to Buy: Here's What You Should Know
Zymeworks Inc. (ZYME) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zymeworks (ZYME) Up After Jazz Exercises Option for Cancer Drug
Following positive data from a mid-stage study evaluating Zymeworks' (ZYME) lead candidate, Jazz (JAZZ) exercises its option to acquire the rights to develop and market this candidate.
Zymeworks nabs $350M from Jazz Pharmaceuticals after release of clinical trial data
Zymeworks will receive $350 million from Jazz Pharmaceuticals in return for the right to develop and commercialize Zymeworks' lead drug candidate, zanidatamab, in the U.
Zymeworks Announces Participation in Upcoming Investor Conference
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management...
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
Follows positive top-line clinical data readout from HERIZON-BTC-01 pivotal trial in biliary tract cancers DUBLIN and VANCOUVER, BC , Dec. 21, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JA...
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology company developing multifunctional biotherapeutics, today announced positive topline resul...
Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the upcoming present...
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today presented new clinical data fo...
Zymeworks to Transfer Stock Listing to Nasdaq
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that it has elected ...
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the waiting per...